Skip to content
2000
Volume 14, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026613666131127155703
2014-02-01
2025-09-05
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026613666131127155703
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test